V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20206443 | 20170001 | 1.77 | 74 | Palliative (P) | 2018-10-13 | 2018-12-05 | Atezolizumab | N | null | GEMCITABINE + RT | 101450822 |
| 20206480 | 20170002 | 1.8 | 74.8 | null | 2018-06-14 | 2018-06-14 | PACLITAXEL + RAMUCIRUMAB | 02 | null | CETUXIMAB + IRINOTECAN | 100364677 |
| 20206530 | 20170003 | 1.5 | 71 | null | 2019-05-06 | 2019-05-09 | TEMOZOLOMIDE | 02 | null | CARBOPLATIN + PEMETREXED | 101395576 |
| 20206644 | 20170004 | 1.75 | 63.2 | null | 2019-11-28 | 2019-11-28 | Azacitidine | 02 | null | FLUOROURACIL + RT | 101417379 |
| 20207149 | 20170005 | 1.6 | 81.5 | null | 2018-08-31 | 2019-03-19 | MITOMYCIN | 02 | null | LOMUSTINE | 100672045 |
| 20207338 | 20170006 | 1.58 | 77.1 | null | 2018-06-03 | 2018-07-14 | EOF | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100323762 |
| 20207633 | 20170007 | 1.84 | 14.8 | 03 | 2018-08-26 | 2018-08-30 | Derazantinib | 02 | null | EOF | 101468877 |
| 20207672 | 20170008 | 0 | 80 | null | 2016-05-09 | 2017-07-01 | Pemetrexed | 02 | Y | CABAZITAXEL | 101483646 |
| 20207941 | 20170009 | 1.56 | 98.5 | 03 | 2020-05-29 | 2020-05-31 | COSMIC TRIAL | 02 | N | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 100556932 |
| 20208048 | 20170010 | 1.73 | 88 | null | 2017-09-24 | 2017-11-28 | INTERAACT trial | 02 | N | PAZOPANIB | 101311813 |
| 20208403 | 20170011 | 1.69 | 97 | Palliative (P) | 2021-12-10 | 2021-12-10 | Bevacizumab + Irinotecan + MdG | 2 | null | CYTARABINE | 101228832 |
| 20208450 | 20170012 | 1.53 | 115.6 | Palliative (P) | 2019-08-20 | 2020-10-25 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | 02 | null | CARBOPLATIN + TEYSUNO | 101828578 |
| 20208547 | 20170013 | 1.58 | 108.3 | Palliative (P) | 2017-11-07 | 2017-12-11 | PHITT D Carboplatin/Doxorubicin | 02 | N | BORTEZOMIB + PANOBINOSTAT | 101842607 |
| 20208924 | 20170014 | 0 | 74.3 | Palliative (P) | 2019-01-22 | 2019-01-26 | CYCLOPHOSPHAMIDE | N | N | CISPLATIN + RT | 101629550 |
| 20210102 | 20170015 | 1.57 | 51.4 | null | 2021-10-22 | 2022-05-04 | Rituximab | N | null | IPILIMUMAB + NIVOLUMAB | 101689861 |
| 20210432 | 20170017 | 1.51 | 64.4 | Palliative (P) | 2020-10-31 | 2020-11-27 | TRANSPLANT CAR-T CELLS - AXICABTAGENE CILOLEUCEL | 02 | N | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 100377845 |
| 20210629 | 20170018 | 1.77 | 95.8 | Disease modification (D) | null | 2022-01-03 | CAPECITABINE + IRINOTECAN + Panitumumab | null | null | GEMCITABINE + OXALIPLATIN | 101794725 |
| 20210893 | 20170019 | 1.65 | 0 | null | 2020-12-10 | 2020-12-26 | null | 02 | N | BEVACIZUMAB + FLUOROURACIL + OXALIPLATIN | 101295603 |
| 20210918 | 20170020 | 1.72 | 64.2 | Neo-adjuvant (N) | 2016-09-25 | 2016-09-26 | ECarboX | 02 | Y | CAPECITABINE + IRINOTECAN + OXALIPLATIN | 100555649 |
| 20210988 | 20170021 | 1.9 | 46.9 | null | 2018-05-24 | 2018-05-24 | ESPAC-4 TRIAL | 02 | N | INTERAACT TRIAL | 101618503 |
| 20211333 | 20170022 | 1.75 | 66 | Curative (C) | 2015-09-09 | 2018-10-16 | Obinutuzumab | 02 | Y | EPIRUBICIN | 101221870 |
| 20211578 | 20170023 | 1.81 | null | Palliative (P) | 2020-05-19 | 2020-05-19 | Cyclophosphamide High Dose | 02 | N | BORTEZOMIB + RITUXIMAB | 100774675 |
| 20211673 | 20170024 | 0 | 0 | Adjuvant (A) | 2016-03-12 | 2018-09-13 | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | 02 | N | PHITT D SIOPEL-4 (A1, A2, A3) | 100408345 |
| 20212058 | 20170025 | 1.72 | 82 | 03 | 2018-12-16 | 2019-11-20 | CAP + RT | 02 | Y | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 101481757 |
| 20212094 | 20170026 | 1.61 | 58 | Palliative (P) | 2019-11-27 | 2019-12-02 | ECF | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100203168 |
| 20212109 | 20170027 | 1.83 | 100.55 | Palliative (P) | 2019-02-08 | 2019-02-15 | CAPECITABINE + LOMUSTINE | 02 | N | FLUOROURACIL + RT | 101414463 |
| 20212138 | 20170028 | 1.8 | 10.5 | Disease modification (D) | 2017-05-23 | 2017-12-28 | IBRUTINIB | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100461963 |
| 20212294 | 20170029 | 1.56 | 93 | null | 2019-11-12 | 2019-12-24 | TEMOZOLOMIDE | 02 | null | SCOPE2 TRIAL | 100988487 |
| 20212591 | 20170030 | 1.77 | null | Curative (C) | 2021-03-13 | 2021-03-13 | Temozolomide 150mg/m2 | 02 | null | RADIUM 223 | 101849529 |
| 20213063 | 20170031 | 1.14 | 79 | null | 2018-05-24 | 2018-05-25 | CHOP - 14 days | 02 | null | CARBO + FLUOROURACIL | 100186456 |
| 20213191 | 20170033 | 1.84 | 81.5 | Curative (C) | 2021-10-04 | 2021-11-15 | PACLITAXEL + RAMUCIRUMAB | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101484197 |
| 20214103 | 20170035 | 1.54 | 115.9 | null | 2017-03-06 | 2017-03-14 | CAPECITABINE + LOMUSTINE | N | null | CARBO + FLUOROURACIL | 100473129 |
| 20214585 | 20170037 | 1.6 | 64.6 | null | 2018-08-12 | 2018-09-13 | AFLIBERCEPT + FLUOROURACIL + IRINOTECAN | 02 | null | CARBOPLATIN + PEMETREXED | 100678103 |
| 20214764 | 20170038 | 1.56 | 51.7 | Curative (C) | 2017-07-27 | 2017-07-27 | Carboplatin + Vinorelbine IV | 02 | null | CAPITAL TRIAL | 101579208 |
| 20214936 | 20170040 | 1.55 | 47.9 | Palliative (P) | 2019-01-14 | 2019-01-16 | Cyclophosphamide High Dose | 02 | N | LETROZOLE + PALBOCICLIB | 101831960 |
| 20215650 | 20170044 | 1.65 | null | null | 2019-12-15 | 2020-08-03 | IDELALISIB | 02 | null | CARBOPLATIN + PEMETREXED | 100892795 |
| 20215671 | 20170045 | 1.58 | 46.35 | null | 2014-03-30 | 2018-01-08 | ESHAP R | 02 | N | CETUXIMAB + IRINOTECAN | 101362840 |
| 20215936 | 20170046 | 1.69 | 81.4 | Curative (C) | 2019-05-29 | 2019-05-29 | MITOMYCIN | N | N | STS RHABDO VIT0910 VINC IRINO TEMOZ | 101630201 |
| 20216410 | 20170048 | 1.8 | 0 | Palliative (P) | 2019-07-18 | 2019-08-26 | DOXORUBICIN | 01 | null | ETOPOSIDE | 101170759 |
| 20216432 | 20170049 | 1.8 | 62.8 | Palliative (P) | 2021-11-11 | 2021-11-16 | BCG Intravesical | 02 | null | NAB-PACLITAXEL | 101148368 |
| 20216542 | 20170050 | 1.75 | 74 | Neo-adjuvant (N) | 2021-04-24 | 2021-07-04 | CAV | N | N | BEVACIZUMAB + CAPECITABINE + IRINOTECAN | 100867680 |
| 20217055 | 20170053 | 1.82 | 115.9 | Curative (C) | 2021-01-21 | 2021-01-28 | Atezolizumab | 02 | n | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 101175464 |
| 20217411 | 20170054 | 1.65 | 76.9 | Palliative (P) | 2017-12-14 | 2018-01-14 | null | 02 | N | BACILLUS CALMETTE-GUERIN | 101264157 |
| 20217473 | 20170055 | null | null | Adjuvant (A) | 2020-09-11 | 2020-09-11 | Cisplatin +FU +Trastuzumab - Maint | 02 | Y | BEVACIZUMAB + FLUOROURACIL + OXALIPLATIN | 101055865 |
| 20217550 | 20170056 | 1.84 | 50.7 | Palliative (P) | 2019-09-15 | 2019-09-15 | CAP + RT | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 101585541 |
| 20217723 | 20170057 | 1.82 | 53.9 | null | 2021-08-14 | 2021-09-14 | Ixazomib + Lenalidomide | 02 | null | LETROZOLE + PALBOCICLIB | 100683398 |
| 20217738 | 20170058 | 1.75 | 83.4 | null | 2017-05-26 | 2017-06-02 | STS Non-Rhabdo EpSSG 2005 IVA | 01 | N | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 101110137 |
| 20218158 | 20170059 | 1.61 | 59 | Palliative (P) | 2020-11-21 | 2020-12-02 | ABEMACICLIB + FULVESTRANT | 02 | N | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 100994352 |
| 20218161 | 20170060 | 1.85 | 88.2 | Neo-adjuvant (N) | 2019-08-26 | 2019-08-29 | ECarboX | 02 | N | BENDAMUSTINE + CYTARABINE + RITUXIMAB | 100382991 |
| 20219725 | 20170062 | 1.77 | 0 | 03 | 2021-07-22 | 2021-07-22 | null | 02 | N | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 100434847 |